BillionToOne Unity sgNIPT
Sep 30, 2022
Molecular diagnostics company BillionToOne has launched its fetal antigen single-gene non-invasive prenatal test (sgNIPT) as part of the firm's Unity Screen. The test is used in pregnant patients who are alloimmunized with C, c, D, E, Duffy, or Kell red blood cell antibodies to identify genetic variants that code for corresponding fetal antigens. The test is used at 10 or more weeks of gestation in patients who doctors suspect are at elevated risk of hemolytic disease of the fetus and newborn (HDFN).